Isabella Tilmont

Ms. Isabella Tilmont

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
Purpose: Folate receptor α (FRα) is expressed in most ovarian cancers. However, only patients with high expression levels are eligible for Elahere, an FRα-targeted microtubule inhibitor antibody–drug conjugate (ADC). Efficacy limitations and safety concerns underscore the need to develop next-generation FRα-targeted ADC to treat tumors expressing variable levels of FRα and incorporate different payloads to reduce safety risks. Herein, we present the characterization of AZD5335, a novel FRα-targeted topoisomerase-1 inhibitor ADC. Experimental Design: The efficacy of AZD5335 was assessed and correlated with FRα expression using cell- and patient-derived models. Focusing on models with low FRα, AZD5335 was directly compared with an Elahere analogue. Additionally, AZD5335 was evaluated in a model of acquired Elahere resistance. Combined treatments, including AZD5335 plus either standard-of-care drugs or a PARP1 inhibitor, were also explored. Results: A single dose of AZD5335 (2.5 mg/kg) achieved an overall response rate of 82% in patient-derived ovarian cancer xenografts (n = 17). Antitumor responses were observed in models expressing both high and low levels of FRα. Specifically within FRα-low models, AZD5335 demonstrated superiority over an Elahere analogue. In the context of acquired Elahere resistance, AZD5335 treatments resulted in complete tumor regressions. Additionally, combining AZD5335 with standard-of-care drugs or a PARP1 inhibitor resulted in enhanced efficacy and sustained durability. Two clinical case studies that demonstrated significant AZD5335 responses in tumors exhibiting high and low FRα expression are also provided. Conclusions: AZD5335 is a promising next-generation ADC capable of targeting ovarian cancers with both high and low FRα expression. AZD5335 demonstrates efficacy in overcoming Elahere resistance and supports combined treatment strategies.

11 October 2025 in Fishes
Verified
Journal Article
Open access
PDF file
AVAndrew James Velkey
Andrew James Velkey
KWKate Watson
Kate Watson
NWNathan White
Nathan White
AAAbigail Agi
Abigail Agi
GAGrace Doebler Alligood
Grace Doebler Alligood
Kaitlyn KinslowKaitlyn Kinslow
Kaitlyn Kinslow
In their natural habitat, male Betta splendens are territorial resource defenders, whereas females are non-territorial opportunistic foragers. This ecological difference suggests that males may be more capable of delaying gratification for food rewards. The present study examined impulsive choice in Betta splendens through two experiments comparing subjects’ choices between a Smaller-Sooner (SS) reward (1 pellet immediately) and a Larger-Later (LL) reward (3 pellets after 15 s). In Experiment I, the choice distributions of males were more likely to stabilize on the LL option over the SS option, whereas females’ choice distributions were equally likely to stabilize on either option. These findings indicate that most males demonstrated spontaneous behavioral self-control without specialized training, while females were collectively indifferent. Experiment II investigated whether dopamine modulates this behavior by administering oral L-Dopa (60 mg/kg) to males before trials. Using the same procedures, only 30% of L-Dopa-treated males’ choice distributions stabilized on the LL reward, while 70% of experimental males’ choice distributions stabilized on the SS option; the choice distributions of control males were equally likely to stabilize on either reward. These results suggest that elevated dopaminergic activity increases impulsive choice in male Betta splendens. Future studies should examine dopamine agonists and antagonists, as well as female responses, to further clarify dopamine’s role in reward valuation and behavioral self-control in Betta splendens.

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
Assessment of AZD5335/TOP1i-mediated DDR.

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
AZD5335 Pharmacokinetic Parameters

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
Purpose:Folate receptor α (FRα) is expressed in most ovarian cancers. However, only patients with high expression levels are eligible for Elahere, an FRα-targeted microtubule inhibitor antibody–drug conjugate (ADC). Efficacy limitations and safety concerns underscore the need to develop next-generation FRα-targeted ADC to treat tumors expressing variable levels of FRα and incorporate different payloads to reduce safety risks. Herein, we present the characterization of AZD5335, a novel FRα-targeted topoisomerase-1 inhibitor ADC.Experimental Design:The efficacy of AZD5335 was assessed and correlated with FRα expression using cell- and patient-derived models. Focusing on models with low FRα, AZD5335 was directly compared with an Elahere analogue. Additionally, AZD5335 was evaluated in a model of acquired Elahere resistance. Combined treatments, including AZD5335 plus either standard-of-care drugs or a PARP1 inhibitor, were also explored.Results:A single dose of AZD5335 (2.5 mg/kg) achieved an overall response rate of 82% in patient-derived ovarian cancer xenografts (n = 17). Antitumor responses were observed in models expressing both high and low levels of FRα. Specifically within FRα-low models, AZD5335 demonstrated superiority over an Elahere analogue. In the context of acquired Elahere resistance, AZD5335 treatments resulted in complete tumor regressions. Additionally, combining AZD5335 with standard-of-care drugs or a PARP1 inhibitor resulted in enhanced efficacy and sustained durability. Two clinical case studies that demonstrated significant AZD5335 responses in tumors exhibiting high and low FRα expression are also provided.Conclusions:AZD5335 is a promising next-generation ADC capable of targeting ovarian cancers with both high and low FRα expression. AZD5335 demonstrates efficacy in overcoming Elahere resistance and supports combined treatment strategies.

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
Characterization of FRa ADC AZD5335.